TABLE 1.
| Viral target | GRP-71271 |
GRP-103594 |
GRP-115249 |
|||
|---|---|---|---|---|---|---|
| EC50 (μM) | EC90 (μM) | EC50 (μM) | EC90 (μM) | EC50 (μM) | EC90 (μM) | |
| IAV-WSN (H1N1)b | 0.17 (0.11–0.25) | 0.34 (0.16–0.73) | 0.28 (0.15–0.51) | 0.36 (0.30–0.43) | 0.38 (0.36–0.39) | 0.84 (0.73–0.97) |
| IAV-WSN-nanoLuc (H1N1)c | 0.05 (0.03–0.08) | 0.310 (0.21–0.45) | 0.02 (0.01–0.04) | 0.321 (0.26–0.38) | 0.06 (0.04–0.09) | 0.46 (0.31–0.69) |
| IAV-NL-nanoLuc (H1N1)c | 0.20 (0.15–0.27) | 0.55 (0.30–1.00) | 0.09 (0.05–0.16) | 0.42 (0.12–1.40) | 0.03 (0.01–0.08) | 0.25 (0.09–0.70) |
| A/Mallard/Potsdam/83 (H2N2)b | 5.36 (3.11–9.30) | 15.5 (3.6–50.5) | >20d | >10e | ||
| A/Panama/2007/99 (H3N2)b,e | >10 | >10 | >10 | |||
| A/Wisconsin/67/2005 (H3N2)b,e | >10 | >10 | >10 | |||
| A/Wyoming/03/2003 (H3N2)b,e | >10 | >10 | >10 | |||
| A/Aichi/2/68 (H3N2)b,e | >10 | >10 | >10 | |||
| Measles viruse,f | >10 | >10 | >10 | |||
| Respiratory syncytial viruse,f | >10 | >10 | >10 | |||
| Sindbis virusb,e | >10 | >10 | >10 | |||
| Vaccinia virusb,e | >10 | >10 | >10 | |||
| Vesicular stomatitis virusc,e | >10 | >10 | >10 | |||
a
Values represent three independent repeats and were calculated through four-parameter variable-slope regression modeling. Values in parentheses specify 95% confidence intervals.
b
Data are based on plaque titers.
c
Data are based on relative RLUs.
d
The highest concentration assessed was 20 μM.
e
The highest concentration assessed was 10 μM.
f
Data are based on TCID50 values.
g
For IAVs, the CC50 value as assessed on BEAS-2B cells was >100 μM (the highest concentration assessed was 100 μM) for all three compounds, and the SI values were >500, >1,100, and >3,300 for GRP-71271, GRP-103594, and GRP-115249, respectively.